C Simard

Statistics

Publications

Citations

7.2K

H-Index

Active since

2017

Affiliations

Vertex Pharmaceuticals (United States)(Current)

National Jewish Health

German Center for Lung Research

St. Vincent's University Hospital

University of Alabama at Birmingham

C Simard is an author at Vertex Pharmaceuticals (United States) specializing in ivacaftor therapy, cystic fibrosis, and cystic fibrosis pharmacotherapy.

Publications per year

2017–2024

Publications

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

Life Sciences, Genetics, Pharmacology +14

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

Jennifer L. Taylor‐Cousar, À. Munck, Edward F. McKone et al. · New England Journal of Medicine · 2017 · 778 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

D. Keating, Gautham Marigowda, Lucy Burr et al. · New England Journal of Medicine · 2018 · 727 citations · Full text

Pharmacy, Molecular Genetics, Pharmacotherapy +13

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

Steven M. Rowe, Cori Daines, Felix C. Ringshausen et al. · New England Journal of Medicine · 2017 · 511 citations · Full text

Medicine, Genetics, Molecular Genetics +13

1–5 of 13